ASX health stocks in the US market: These 2 companies had good news this morning

Nick Sundich Nick Sundich, November 20, 2023

ASX health stocks in the US market have the odds stacked against them, but 4DMedical (ASX:4DX) and Artrya (ASX:AYA) received news that place them in good position to succeed in the market.


4DMedical gets a non-negotiable asset for ASX health stocks in the US market

To sell in the US market, ASX health stocks require FDA approval for their drug or medical device. 4DMedical told its investors that its CT-based ventilation product CT LVAS received regulatory clearance.

This is the second product that 4d Medical has approved in the FDA approval, with the first being XV LVAS, that is X-ray based rather than CT-based. But both products are Lung Ventilation Analysis Software, by name and by their actions. CT LVAS was already approved in Australia, although the US is easily the larger market for the company.

4D Medical also told shareholders it re-risked the regulatory pathway for its next product, CT:VQ which is a ventilation perfusion product.


4DMedical (ASX:4DX) share price chart, log scale (Source: TradingView)


Good news from Artrya too

Artrya, another company on the list of ASX health stocks trying to make it in the US market, is commercialising Salix, an AI platform that detects key coronary artery disease imaging markets. Although it is not FDA approved just yet, Artrya announced its first commercial deal in the USA. Northeast Georgia Health Ventures and Artrya have entered into a deal to provide Salix to the former group’s patients once it is FDA approved.


Artrya (ASX:AYA) share price chart, log scale (Source: TradingView)


The deal won’t be a case of ‘sit and wait’, however. Preparations will occur while it is going through the approval process and the pair will develop and expand specific use cases for Salix. Artrya told its shareholders that there was a market opportunity of US$320bn ahead of the company and that this deal alone could see it reach 5 hospitals that provide heart disease treatment to over 100,000 per year.


What are the Best ASX Stocks to invest in right now?

Check our ASX buy/sell tips

Recent Posts

johns lyng group

Johns Lyng Group (ASX:JLG): One of a few ways to profit from climate change

Johns Lyng Group (ASX:JLG) is a restoration services company, repairing properties after damage by insured events, including weather and other…

hydrogen in australia

Hydrogen in Australia: Can we expect massive adoption in the next 10 years?

When will we see hydrogen in Australia? Not as a fad, not as an idea, but as a widespread energy…

Why is Gina Rinehart buying into Lynas

Why is Gina Rinehart buying into Lynas? She’s accumulated a stake worth over $300m

The big question on many investors’ minds this week is why is Gina Rinehart buying into Lynas? A substantial notice…